Full-Time

Quality Assurance Specialist 3 / Deputy Responsible Person

Gilead Sciences

Gilead Sciences

10,001+ employees

Biopharmaceutical firm developing HIV/AIDS therapies

No salary listed

London, UK

In Person

Category
QA & Testing (1)
Required Skills
Veeva
SAP Products
Word/Pages/Docs
Excel/Numbers/Sheets
PowerPoint/Keynote/Slides
Requirements
  • University degree in pharmacy, chemistry, medicine, biology or a related natural science
  • Extensive experience in QA/Regulatory Affairs with a Bachelors, Masters or equivalent, experience in the United Kingdom market
  • Must reside in the United Kingdom and be fluent in English (written and spoken)
  • Must be a member of a professional body with a published code of conduct
  • Experience in quality assurance, preferably in the pharmaceutical industry or as deputy responsible person
  • Proficiency in Quality system processes (Deviation, CAPA, Change Control, Complaints, Supplier Management etc)
  • Proficiency in Microsoft Office applications, particularly Word, Excel, PowerPoint, and Teams. Familiarity with technology platforms such as Veeva Vault, SAP, etc.
  • Excellent influencing and negotiation skills
  • High quality awareness, accurate, independent and reliable approach to work
  • Ability to work in a team, work under pressure, flexibility and good communication skills
  • Good organizational skills with well-structured ways of working
  • Must be capable of leading small project teams
  • Must have the ability to work and negotiate with a Health Authority
  • Ability to work on a number of projects with tight timelines
Responsibilities
  • Support management of local Quality Management System (QMS) and ensure that the implemented quality management system is always up to date
  • Support the Responsible Person for import (Rpi). Perform (RPi) activities to ensure compliance of products imported into UK from an approved country on import list as per MHRA guidance for finished medicinal products
  • Manage local Affiliate Change Controls, Deviations & CAPAs relating to GDP
  • Support management of local recall activities and execution/participation in periodic mock product recall challenges
  • Support or manage quality defects, falsified or counterfeit products and stock out as required
  • Manage/Coordinate local complaints & falsified product investigations
  • Manage product returns as required
  • Support supplier management and supplier audits including those of distribution partners in UK
  • Support the drafting and renewing of quality agreements with internal manufacturers and/or external partners
  • Support drafting of Quality Management Reviews
  • Assess Annual Periodic Product Reviews (APQRs) in accordance with the UK marketing authorisation
  • Support the verification of the authorizations of new customers/ existing customers
  • Support inspections by the local Health Authority as well as corporate GDP audits
  • Write and/or implement changes to controlled documents (e.g. SOPs and Quality Manual) as needed
  • Work with 3PL/4PL, provide guidance on supply related issues
  • Work with Product Suppler in relation to GDP activities
  • Support global QA with QA tasks as required
  • Supports RP with the maintainance of the WDA(H), Manufacturers Specials Licence and GMP and MIA (iIMP)mport license in the UK, as required.
  • Act as a delegate contact for RP for the MHRA in the UK on quality issues.
  • Perform Responsible Person for import (RPi) activities to ensure compliance of products imported into UK from an approved country on import list as per MHRA guidance
  • Ensure that the requirements of all relevant national and international guidelines and internal specifications are met with regard to storage and distribution of products and that a compliant Quality System is in place at the Affiliate.
  • Support Customer Services with enquiries of a GDP nature such as delivery issues, transportation conditions, temperature excursions etc.
  • Implement and maintain the SOP/guidance documentation system for UK and review all SOPs depending on the subject matter as a reviewer of content and/or format.
  • Maintain up-to-date knowledge of all nationally applicable pharmaceutical legislation and disseminate this, explain and train employees where necessary.
  • Ensure that initial and continuous GDP training programmes are implemented and maintained, train and educate all personnel as regards applicable pharmaceutical legislation and its practical consequences for the company at a national and international level.
  • Decide on the final disposition of returned, rejected, recalled or falsified products, and approve any returns to saleable stock.
  • Ensure that suppliers and customers are approved and adequate records established and maintained.
  • Approves and maintains an oversight of all subcontractors’ activities which may impact on GMP/GDP.
  • Ensure that self-inspections are performed at appropriate regular intervals following a prearranged programme and necessary corrective measures are put in place.
  • Act as rresponsible contact person for internal GDP audits.
  • Ensure Quality Risk Management and conduct Quality Management Reviews.
  • Keep appropriate records of any delegated duties.
  • Ensure review of Annual Product Quality Reports of all products.
  • Ensure that product receipt, storage and delivery to customers are carried out in compliance with GMP & GDP and in line with the company policies and procedures.
  • Ensure that suppliers and local service providers are audited on a regular basis.
  • Ensure up to date organization charts, job descriptions, Curriculum Vitae and training records are available for personnel in the Affiliate involved in GDP activities.
  • Ensure the filing and archiving of returned goods documentation and recalls is done according to the Gilead records retention policy and national requirements, whichever is longer/ more stringent.
  • Ensure that complaints are handled according to both the local legislation and applicable company procedures.
  • Define initial and ongoing training requirements for Affiliate and third party subcontracted personnel on /GDP and on respective document management.
  • Provide customer support for GDP-related enquiries and complaints.
  • Maintain, approve and sign Quality Agreements with EU Batch release (technical batch release) sites, local GDP service providers as well as ex-vivo cell therapy product apheresis and treatment centres in her/his function as RP.
  • Communicate changes in quality information to project teams and senior management Initiating or contributing to local and / or global process improvements which have a significant impact on the business.

Gilead Sciences discovers, develops, and markets medicines to treat HIV/AIDS, liver diseases, cancer, inflammatory and respiratory diseases, and cardiovascular conditions. Its products reach patients globally after regulatory approval, sold through doctors, hospitals, and pharmacies. The company relies on a large, diverse R&D pipeline and strategic partnerships to expand its therapies and reach, including collaborations like SAP Ariba to improve sourcing. Its goal is to improve health equity by expanding access to medicines and promoting sustainable healthcare practices worldwide.

Company Size

10,001+

Company Stage

IPO

Headquarters

Foster City, California

Founded

1987

Simplify Jobs

Simplify's Take

What believers are saying

  • HIV franchise grows 10% YoY to $20.8 billion in 2025 with no patent cliffs until 2036.
  • Trodelvy oncology sales surge 37% to $253 million in Q1 2026 ahead of H2 expansions.
  • $11.5 billion acquisitions of Arcellx, Ouro, Tubulis add 53-programme pipeline launches by 2027.

What critics are saying

  • Florida delists Biktarvy from AIDS program in May 2026, slashing $20.8 billion HIV revenue.
  • $11.5 billion acquisition charges flip 2026 EPS to $1.05 loss, integration fails by 2027.
  • Biktarvy generics erode 40% revenue post-2034 as regulatory pathways accelerate competition.

What makes Gilead Sciences unique

  • Gilead pioneered complete once-daily HIV regimens like Biktarvy generating $14.3 billion in 2025.
  • Gilead leads with twice-yearly HIV prevention via Yeztugo reaching $166 million Q1 2026 sales.
  • Gilead dominates antiviral therapies across HIV, hepatitis, and COVID-19 since 1987 founding.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Gilead Sciences who can refer or advise you

Benefits

Paid family time off and paid parental time off

Generous 401(k) contribution matching

Comprehensive medical plans that cover both physical and mental healthcare

Global Wellbeing Reimbursement

Time Off

Global Volunteer Day

Giving Together Program

Employee Support Programs

Flexible Work Options

Company News

AllSci
Apr 10th, 2026
Tempus AI expands oncology data collaboration with Gilead Sciences through AI-driven platform access.

Tempus AI expands oncology data collaboration with Gilead Sciences through AI-driven platform access. April 10, 2026 Tempus AI, Inc. (Nasdaq: TEM), a Chicago-based technology company, announced an expanded multi-year collaboration with Gilead Sciences, Inc. (Nasdaq: GILD) aimed at advancing Gilead's oncology pipeline through enterprise-wide access to Tempus's AI-driven Lens platform and multimodal real-world evidence datasets. The agreement covers multiple oncology indications; no specific drug candidates or therapeutic targets were disclosed as part of the transaction. Financial terms were not disclosed. Under the expanded arrangement, Gilead gains enterprise-wide access to the Tempus Lens platform, which integrates de-identified genomic, clinical, imaging, and outcomes data into a unified repository supported by AI-driven analytical tooling. Disclosed applications include trial design, indication selection, biomarker strategy, health outcomes analysis, and clinical real-world evidence generation. Tempus will also provide dedicated analytical services under the agreement. The collaboration represents an expansion of a pre-existing relationship in which Gilead had previously used Tempus data to inform oncology R&D initiatives, and follows on from a collaboration between Tempus and Daiichi Sankyo announced in March 2026. The collaboration is designed to operate across Gilead's oncology pipeline rather than in support of a single program. Gilead's oncology portfolio includes sacituzumab govitecan, axicabtagene ciloleucel, brexucabtagene autoleucel, and magrolimab, among other assets, though none were named as specific beneficiaries of the arrangement. The platform's stated functions - indication prioritization, patient stratification, biomarker pre-validation, and real-world evidence generation - are applicable across tumor types and development stages. Your email address will not be published. Required fields are marked *

Yahoo Finance
Apr 9th, 2026
Gilead exercises option on Kymera's oral CDK2 degrader KT-200, triggering $45M milestone

Kymera Therapeutics will receive a $45 million milestone payment following Gilead Sciences' decision to exercise its option to exclusively licence KT-200, a first-in-class oral CDK2 molecular glue degrader development candidate. Gilead will advance the programme into IND-enabling studies, targeting an IND filing in 2027. KT-200 is expected to become the first molecular glue discovered by Kymera to enter clinical trials. The drug candidate demonstrated low-nanomolar degradation of CDK2 in preclinical testing, with robust activity in cancer cell lines and favourable safety profiles. It targets cancers driven by CCNE1 amplification, including advanced breast cancer. Under their collaboration agreement, Kymera is eligible for up to $750 million in total payments and has received $85 million to date. The company will also receive tiered royalties on net product sales.

Genetic Engineering and Biotechnology News
Apr 7th, 2026
Gilead to acquire Tubulis for up to $5B, expanding cancer ADC capabilities.

Gilead to acquire Tubulis for up to $5B, expanding cancer ADC capabilities. April 7, 2026 Gilead Sciences has agreed to acquire German-based Tubulis for up to $5 billion, the companies said today, in a deal designed to expand the buyer's antibody-drug conjugate (ADC) capabilities with a focus on fighting cancer. Headquartered in Munich, privately held Tubulis has developed next-generation ADC candidates based on its own conjugation, linker and payload technologies intended to more selectively deliver diverse payloads to tumors deemed to be of high unmet need. The companies said Tubulis' programs and platforms have broad potential across multiple tumor types, complementing Gilead's development and commercialization expertise in oncology. "We like the strategic fit and deal terms of the Tubulis (private) acquisition," Daina M. Graybosch, PhD, senior managing director, immuno-oncology and a senior research analyst at Leerink Partners, wrote this morning in a research note. "This is more than an oncology bolt-on; we see real platform value in application of Tubulis' ADC technologies to other therapeutic areas, namely virology." Tubulis' lead pipeline candidate, TUB-040, is a sodium-dependent phosphate transport protein 2B (NaPi2b)-targeting topoisomerase-I inhibitor (TOPO1i) ADC that is now under study in the Phase Ib/II NAPISTAR1-01 trial (NCT06303505) assessing its safety, pharmacokinetics, and preliminary efficacy as a treatment for platinum-resistant ovarian cancer and non-small cell lung cancer (NSCLC). In October at the European Society for Medical Oncology (ESMO), Graybosch noted, Tubulis presented data for TUB-040 showing a confirmed 50% overall response rate (ORR) and a 60% unconfirmed ORR across dose levels and irrespective of target antigen - results that were competitive with more mature datasets from leading TOPO1i ADCs. "Though the dataset was early, and our primary outgoing question was how durability would mature, we suspect that Gilead saw durability maturing positively in their diligence," Graybosch added. "If TUB-040 proves active in NSCLC, the program could complement their Trodelvy and IO [immune-oncology] lung programs. We wonder if Gilead saw early clinical NSCLC data in their diligence and if excitement around the emerging signal drove some of Tubulis' valuation." Another Tubulis pipeline candidate, TUB-030, is a 5T4-targeting ADC that according to the companies has shown promising initial clinical data across various solid tumor types. TUB-030 is currently under study in the Phase I/IIa 5-STAR 1-01 trial (NCT06657222), a first-in-human study which aims to evaluate the safety, tolerability, pharmacokinetics, and efficacy of TUB-030 as a monotherapy in patients with advanced solid tumors. Tubulis has said it is developing TUB-030 for up to 13 undisclosed solid tumor indications. Partners since 2024. The acquisition deal follows a two-year, up-to-$465 million collaboration with Tubulis launched in December 2024. Gilead gained access to Tubulis' Tubutecan and Alco5 platforms after signing an exclusive option and license agreement to discover and develop an ADC against a solid tumor target. At the time, Gilead agreed to pay Tubulis $20 million upfront, received an option that if exercised would have given Tubulis an additional $30 million - plus up to $415 million in payments tied to achieving development and commercialization milestones, as well as mid-single to low double-digit tiered royalties on sales of marketed products resulting from the collaboration. "Today's agreement follows a two-year collaboration with Tubulis, which has given us strong conviction in their programs and research capabilities," Gilead Chairman and CEO Daniel O'Day said in a statement. "The agreement to acquire Tubulis is a significant milestone in Gilead's progress in oncology. The company brings a clinical-stage candidate that is a potential new treatment for ovarian cancer, as well as a next-generation ADC platform and a promising early pipeline." "Bringing this potential into Gilead would further expand what is already the strongest and most diverse pipeline in our company's history," O'Day declared. Investors appeared less enthusiastic about the acquisition, as shares of Gilead dipped 1.7% in early Tuesday trading to $137.80 as of 12:01 p.m. ET. Tubulis is Gilead's third announced acquisition this year. The biotech giant announced plans in March to buy Ouro Medicines for up to $2.18 billion, and in February agreed to acquire Arcellx for up to $7.8 billion - for which it agreed last week to extend its tender offer until 5 p.m. ET on April 24. Under the acquisition deal, Gilead agreed to acquire all of the outstanding equity of Tubulis for $3.15 billion in upfront cash payable at closing, and up to $1.85 billion in payments tied to milestones. The transaction is expected to close in the second quarter subject to expiration or termination of specified regulatory filings and other customary conditions. Upon closing of the deal, Tubulis will operate as a dedicated ADC research organization within Gilead, with the Munich site serving as a hub for ADC innovation, building on its integrated discovery, manufacturing, and clinical capabilities to advance next generation ADCs. Gilead said it plans to finance the transaction with a combination of cash on hand and senior unsecured notes. Gilead finished 2025 with $10.605 billion of cash, cash equivalents and marketable debt securities, up from $9.991 billion as of December 31, 2024.

Dealroom.co
Apr 7th, 2026
Gilead Sciences company information, funding & investors

Gilead Sciences, biopharmaceutical company that discovers, develops, manufactures and commercializes therapies for critical diseases. Here you'll find information about their funding, investors and team.

Mednext Healthcare
Apr 7th, 2026
EQT Life Sciences to exit minority stake in Tubulis via sale to Gilead Sciences for up to USD 5.0 billion.

EQT Life Sciences to exit minority stake in Tubulis via sale to Gilead Sciences for up to USD 5.0 billion. Up next. Published on 07 April 2026 EQT Life Sciences plans to sell its stake in Tubulis to Gilead Sciences. * EQT Life Sciences sells stake in Tubulis to Gilead Sciences. * The transaction could be valued at up to $5 billion. * This sale marks a significant shift in EQT's investment strategy. EQT Life Sciences is preparing to sell its minority stake in the biopharmaceutical company Tubulis to Gilead Sciences. This strategic move is expected to generate a total value of up to $5 billion. The transaction highlights the growing interest by major firms in innovative therapeutic developments. Gilead Sciences aims to leverage Tubulis's advancements in biopharmaceuticals through this acquisition. The sale reflects EQT Life Sciences' approach to capitalizing on its investments in the life sciences sector. Both companies anticipate that this deal will accelerate the delivery of critical therapies to patients. As part of this transaction, EQT Life Sciences is expected to reallocate its resources towards new investment opportunities within the life sciences arena. The sale aligns with industry trends favoring the consolidation of innovative technologies in the biopharmaceutical space.